Analytical Data
-
Gene name
HLA-A*02:01&B2M&Glypican 3(FVGEFFTDV) Monomer
- Application
-
Alternative Names
HLA-A*02:01&B2M&Glypican 3 (FVGEFFTDV)
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
AAA59606.1 (G25-I308)&P61769
-
Expression Region
AAA59606.1 (G25-I308)&P61769 (I21-M119)&FVGEFFTDV
-
Molecular Weight
42-45 kDa and 14 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
HLA-A*02:01 is a widely studied human leukocyte antigen known for its critical role in the immune response, specifically in the presentation of peptide antigens to T cells. It is commonly associated with various diseases, including cancers and viral infections. In this context, the glypican-3 (GPC3) protein, particularly the peptide FVGEFFTDV derived from it, has gained attention as a tumor-associated antigen. GPC3 is overexpressed in several malignancies, particularly in hepatocellular carcinoma, making it a promising target for immunotherapy. The recombinant protein consisting of HLA-A*02:01, beta-2 microglobulin (B2M), and the GPC3 peptide FVGEFFTDV is being investigated to facilitate the understanding of T cell responses and to potentially enhance the development of novel cancer vaccines. This research aims to elucidate the structural and functional aspects of the peptide-MHC (Major Histocompatibility Complex) interaction, which is crucial for T cell recognition and activation. Understanding these interactions at the molecular level could pave the way for effective immunotherapeutic strategies targeting tumors expressing GPC3, ultimately contributing to improved treatment options for patients suffering from GPC3-positive cancers.
